Tasigna in Glivec-resistant or Intolerant Patients in CML
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate efficacy and safety of nilotinib in patients with
Imatinib resistant or intolerant CML-CP or AC. Efficacy evaluation will be made by Complete
cytogenetic response rate(CCyR) at 12 months after nilotinib administration.